Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants
Author Information
Author(s): Suzuki Shuhei, Saito Yosuke, Saito Koki, Yamada Yuta, Takahashi Koshi, Kumanishi Ryosuke, Fukui Tadahisa, Yoshioka Takashi
Primary Institution: Yamagata University
Hypothesis
Do rare RAS variants affect the efficacy of anti-EGFR therapy in colorectal cancer patients?
Conclusion
Patients with rare RAS variants have significantly lower response rates to anti-EGFR therapy compared to those with RAS wild-type.
Supporting Evidence
- 54 patients (1.3%) with rare RAS variants were identified.
- Response rates for patients with rare RAS variants were 28.3%, compared to 44.6% for RAS wild-type cases.
- Disease control rates were 60.9% for rare variant cases versus 80.0% for wild-type cases.
- Comprehensive genomic profiling revealed additional alterations in TP53 (90.7%) and APC (87.0%).
Takeaway
Some people with a specific type of cancer have rare gene changes that make their medicine not work as well, so doctors need to check for these changes before giving treatment.
Methodology
The study analyzed data from the C-CAT database, focusing on colorectal cancer patients treated with anti-EGFR antibodies and identifying those with rare RAS variants.
Potential Biases
Potential bias due to the retrospective nature of the study and reliance on existing database records.
Limitations
The study's analysis was based on amino acid changes without confirming specific nucleotide alterations, and it included gastrointestinal cancers broadly, which may introduce heterogeneity.
Participant Demographics
Median age of patients with rare RAS variants was 62 years, with an equal gender distribution (27 males and 27 females).
Statistical Information
P-Value
0.003
Confidence Interval
95% Confidence Interval: 15.2–41.3%
Statistical Significance
p = 0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website